The Serum Institute of India, one of the world’s largest vaccine manufacturers, has been producing tens of millions of doses of COVISHIELD, the candidate developed between AstraZeneca and the University of Oxford, and is now seeking emergency approval to distribute them in India. One of the main advantages of the AstraZeneca candidate is that it can be stored at normal refrigerator temperatures, unlike other candidates that require extreme cold. If approved, Serum Institute has indicated it can sell the vaccine to the Indian government for as little as the equivalent of CAD$4 per dose.